SIGA Technologies and Cipla Therapeutics – executive interview

Published on 15 June 2021

SIGA Technologies (Nasdaq: SIGA) is a commercial-stage company focusing on health security. Its lead program is oral TPOXX (tecovirimat), which was approved by the FDA in 2018 for the treatment of smallpox and is active against all orthopoxviruses. In this video, SIGA’s CEO, Dr Phillip Gomez, and Garrett Ingram, President, CEO of Cipla Therapeutics, discuss the companies’ recently announced partnership. This collaboration will provide the Biomedical Advanced Research and Development Authority (BARDA) with solutions for its biothreat and public health needs, with a particular focus on tackling antimicrobial resistance (AMR). Find out more about SIGA Technologies (SIGA) in Edison’s initiation report.

Share this with friends and colleagues